Skip to content

Comparing the outcome of two protocols in poor responders in ART cycles

Microflare protocol vs Flare up Protocol in Poor Responders in ART cycles

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT138806031141N4
Enrollment
200
Registered
2009-11-10
Start date
2008-08-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor ovarian response. other mathernal disorders predominantly related to pregnancy

Interventions

Intervention 1: Patients were pretreated for 21 days with OCP. Busereline (80 µg s.c.) is administered from day 2 or 3 of cycle. Gonal F at dose of 225-450 IU/day i.m is started according to the patie
Treatment - Drugs
Patients were pretreated for 21 days with OCP. Busereline (80 µg s.c.) is administered from day 2 or 3 of cycle. Gonal F at dose of 225-450 IU/day i.m is started according to the patients' situation a
Patients were pretreated for 21 days with OCP. Busereline (500 µg s.c.) is administered from day 2 or 3 of cycle. Gonal F at dose of 225-450 IU/day i.m is started according to the patients' situation

Sponsors

Royan Institute
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
No minimum to 42 Years

Inclusion criteria

Inclusion criteria: history of oocyte number less than 3 (in previous cycle) 3. number of antral follicle less than 5 in previous cycle 4. age more than 38 years 5. FSH>12 on day 2 or 3 6. Ovarian Volume 3 cubic centimeter Exclusion Criteria: Male factor (azospermi), Myoma = 6cm, single ovary, tumor or cyst with size more than 13mm, age more than 42

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pregnancy rate. Timepoint: Two weeks after embryo transfer. Method of measurement: ß-hCG.

Secondary

MeasureTime frame
Cycle cancellation rates. Timepoint: 6 weeks. Method of measurement: Number of sac.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ghaffari

Royan Institute

tmadani@royaninstitute.org+98 212362307

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026